Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options

Anagnostis, Panagiotis; Karras, Spyridon Ν.; Lambrinoudaki, Ιrene; Stevenson, John C.; Goulis, Dimitrios G.

doi:10.1111/ijcp.12903

Cited by 31 publications

(12 citation statements)

References 108 publications

(272 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 After menopause, the reduced activity of the ovaries is leading to a reversal of lipid distribution and disorders in the distribution of lipoprotein. 1,8 Ovaries produce oestrogen, which is the main sexual hormone in women. Oestrogen affects many organs and protects against CD by regulating hepatic lipid metabolism and serum lipoprotein levels.…”

Section: Introductionmentioning

confidence: 99%

“…Menopause is defined by the World Health Organization as a fertility stop because of the loss of follicular ovarian function or ovarian removal by surgery, at an average age of 50, and one year after the last menstruation 7 . After menopause, the reduced activity of the ovaries is leading to a reversal of lipid distribution and disorders in the distribution of lipoprotein 1,8 . Ovaries produce oestrogen, which is the main sexual hormone in women.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects ofElaeagnus angustifoliaL. on lipid and glycaemic profiles and cardiovascular function in menopausal women: A double‐blind, randomized, placebo‐controlled study

Shabani

Rezaei

Badehnoosh³

et al. 2020

Int J Clin Pract

View full text Add to dashboard Cite

Aims The reduced production of ovarian hormones is considered to be the cause of an increase in the incidence of heart disease in women after menopause. Phytoestrogens are found in various herbal sources and are considered as an alternative to hormone therapy because of structural similarity with oestrogen. Elaeagnus angustifolia L., known as Senjed in Persian, is used in Iranian traditional medicine with various medicinal properties, contains valuable compounds, including two types of phytoestrogens. The aim of the present study was to investigate the efficacy of E. angustifolia fruit on the cardiovascular function, lipid and glycaemic profiles in postmenopausal women. Methods In this double‐blind placebo‐controlled clinical trial, 58 postmenopausal women were randomly assigned into two experimental groups of medicinal herb (15 g/day of the whole E. angustifolia fruit powder) and placebo (15 g/day of isomalt + corn starch). Before the trial and after 10 weeks of the treatment, cardiovascular function (heart rate, blood pressure), serum glycaemic profile (fasting blood glucose; glycated haemoglobin, HbA1C), insulin and lipid profile (total cholesterol, TC; triglyceride, TG; LDL‐C and HDL‐C) were measured. Results Heart rate, and serum level of LDL‐C and HDL‐C significantly decreased after treatment with E. angustifolia. Changes in glycaemic profile were not clinically significant. In addition, some studied biochemical parameters significantly changed in the placebo group. Conclusions E. angustifolia was somewhat effective in improving cardiovascular function and lipid profile, as well as the overall health of postmenopausal women. However, the use of isomalt and corn starch in menopausal women needs further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effects ofElaeagnus angustifoliaL. on lipid and glycaemic profiles and cardiovascular function in menopausal women: A double‐blind, randomized, placebo‐controlled study

Shabani

Rezaei

Badehnoosh³

et al. 2020

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…Hormonal replacement therapy is associated with lower Lp(a) levels, with oral oestradiol leading to larger decreases than transdermal application 15 . Mainly oral oestrogens and tibolone have been specifically studied in postmenopausal women and can reduce Lp(a) concentrations by up to 44%, although evidence indicating a concomitant reduction in CVD risk associated with Lp(a) is lacking 37 . The exact mechanism of the modulation of Lp(a) levels with HRT is still unclear, and our results could be interpreted as an argument against a causal effect of HRT on cardiovascular risk mediated by Lp(a).…”

Section: Discussionmentioning

confidence: 99%

Changes of lipoprotein(a) levels with endogenous steroid hormones

Tessitore

Dobretz

Dhayat

et al. 2021

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…It is worth mentioning that certain other estrogen-related agents, such as tibolone and tamoxifen, are being evaluated for their effect on Lp(a). Tibolone is a synthetic steroid with estrogenic, progestogenic, and androgenic properties, which has been shown to cause significant decreases in Lp(a) levels 43. In a systematic review and meta-analysis of 12 studies including a total of 1009 patients, treatment with tibolone led to a 25.28% mean reduction in Lp(a) levels in postmenopausal women 44.…”

Section: Estrogen/hormone Replacement Therapymentioning

confidence: 99%

Therapeutic management of hyperlipoproteinemia (a)

Kosmas¹,

Sourlas²,

Mallarkey³

et al. 2019

DIC

View full text Add to dashboard Cite

Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as well as calcific aortic valve stenosis. Thus, the therapeutic management of hyperlipoproteinemia (a) has received much attention, as significant reductions in Lp(a) levels may, potentially, favorably affect cardiovascular risk. Aspirin, niacin, estrogens, and statins, which act on different molecular pathways, may be prescribed to patients with mild or modest elevations of Lp(a) levels. Other therapeutic interventions, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, and the novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx, which are being evaluated in ongoing clinical trials, have provided some promising results and can potentially be used in severe cases of hyperlipoproteinemia (a). This review aims to present and discuss the current clinical and scientific data pertaining to the therapeutic options for the management of hyperlipoproteinemia (a).

show abstract

Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options

Abstract: Past, present and emerging therapies can reduce Lp(a) concentrations to a varying extent. Overall, it remains to be proven whether the aforementioned reductions in Lp(a) by these therapeutic options are translated into CVD risk reduction in postmenopausal women.

Cited by 31 publications

References 108 publications

The effects ofElaeagnus angustifoliaL. on lipid and glycaemic profiles and cardiovascular function in menopausal women: A double‐blind, randomized, placebo‐controlled study

The effects ofElaeagnus angustifoliaL. on lipid and glycaemic profiles and cardiovascular function in menopausal women: A double‐blind, randomized, placebo‐controlled study

Changes of lipoprotein(a) levels with endogenous steroid hormones

Therapeutic management of hyperlipoproteinemia (a)

Contact Info

Product

Resources

About